The company's research and development expenses decreased to $51.7 million, reflecting a focus on efficiency and restructuring initiatives. Despite the increased product sales, Travere reported a net loss of $54.8 million for the quarter, mainly due to high operating costs and ongoing investments in development programs. Travere Therapeutics is strategically positioned to accelerate the growth of FILSPARI, with ongoing discussions with the FDA regarding additional indications and modifications. Moreover, their European partner has begun the commercial launch of FILSPARI in select countries, indicating a potential for further international expansion. Looking ahead, Travere Therapeutics aims to strengthen its market presence with FILSPARI and explore additional therapeutic areas. The management remains optimistic about future growth prospects, supported by ongoing clinical trials and strategic partnerships.